U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07047326) titled 'Urokinase for Thrombolysis in Acute Ischemic Stroke' on June 24.
Brief Summary: According to the Chinese Guidelines for the Diagnosis and Treatment of Ischemic Stroke, intravenous thrombolysis with urokinase, administered at doses of 1-1.5 million IU within 6 hours of symptom onset, has been shown to be both safe and effective for patients with acute ischemic stroke. Compared to alteplase, urokinase offers considerable cost advantages while maintaining comparable therapeutic efficacy. However, current dosing protocols in clinical practice largely rely on the empirical judgment of physicians rather than evidence-based standardization....